Abstract
Despite the advancements in cancer treatment, ovarian cancer's five-year survival rate remains below 50%. PARP inhibitors, targeting cancer cells with defects in DNA repair, present a promising treatment. However, concerns about drug resistance and side effects demand further research. One target gaining interest is PARP7 and inhibitors are shown to restore type I interferon signaling responses, leading to tumor regression. While no approved PARP7 inhibiting pharmaceuticals currently exist, this Patent Highlights showcase compounds and formulations with potential as potent PARP7 inhibitors, marking a new path for cancer therapy. PARP7 inhibitors could be instrumental in treating various cancers and immunological diseases, and with further understanding, may improve patient outcomes.